DS-6157临床前数据发表在2021年2月份的Cancer Discovery杂志(IF:39.397),主要引起大家关注的是其作用靶点GPR20,其不仅在kit突变GIST中表达,在野生型GIST中同样有部分高表达,这意味着未来或许能够出现一个无论对突变型还是野生型都能有效的新型药物,笔者特别期待...
(41% of all positive tests) performed on 7-8 January 2021 in France. The prevalence of 20I/501Y.V1 was 3.3% among positive tests nationwide and 6.9% in the Paris region. Analysing the recent rise in ...
序贯载荷下考虑泊松比的药柱结构完整性分析[501-510] 陆传军,王学仁,强洪夫 DOI:10.7673/j.issn.1006-2793.2024.04.009 浏览(54)[HTML](1)引用导出PDF下载(98)扫码 基于光纤和柔性传感器的固体火箭发动机结构监测技术研究[511-518] 李双江,刘向阳,章喆,张晋尚,郭浩然 ...
Chem Pharm Bull (Tokyo). 2023; 71(7):495-501.Matsumoto T, Yoshikawa H, … Watanabe TCP We isolated the new sesquiterpenes, valerianaterpenes IV and V, and the new lignans valerianalignans I-III from the methanol extracts of the rhizomes and roots of Valeriana fauriei and elucidated their ...
17 0 0 0 1 5 5 6 7 18 15 11 0 3 0 0 0 2 1 4 5 11 7 13 10 18 0 37 65 135 192 198 225 345 395 392 340 424 628 54 97 195 282 300 337 481 570 544 501 570 878 The top 11 publishers hold 70.3% (3405/4844) of retracted articles and 66% (1165/1767) of journals....
Reza Taheri-Ledari * and Ali Maleki * Received 17th November 2021 Accepted 19th January 2022 DOI: 10.1039/d1na00818h rsc.li/nanoscale-advances Herein, a concise review of the latest developments in catalytic processes involving organic reactions is presented, focusing on magnetic catalytic systems ...
J Comp Physiol B Biochem Syst Environ Physiol 159(4):501–508 Packard GC, Taigen TL, Boardman TJ, Packard MJ, Tracy CR (1979) Changes in mass of softshell turtle (Trionyx spiniferus) eggs incubated on substrates differing in water potential. Herpeto- logica, 78–86...
F. G. 2021, "The non-monotonic, strong metallicity dependence of the wide-binary fraction", Monthly Notices of the Royal Astronomical Society, 501, 4329 24. Hwang, H.-C., Hamer, J. H., Zakamska, N. L., & Schlaufman, K. C. 2020, "Very wide companion fraction from Gaia DR2: ...
024 442 Other noncurrent liabilities 774 501 Total noncurrent liabilities 15,289 6,744 Shareholders' equity Ordinary shares (470.7 million outstanding in 2012 and 334.4 million in 2011) 5 167 Capital in excess of par value 11,271 4,169 Retained earnings 5,805 5,103 Accumulated other ...
501 1202 2006 2092 2182 2276 2375 2479 2587 2700 2818 2942 3071 3206 3348 3497 3654 3818 3989 4167 4353 4547 4750 4961 0 502 1206 2011 2097 2187 2282 2382 2485 2593 2706 2824 2947 3076 3212 3354 3503 3660 3823 3994 4173 4359 4553 4756 4967 0 504 1210 2017 2103 2194 2289 2389 2492...